InnovaRx Innova Health Strategies

D69.4

Other primary thrombocytopenia

Not billable — category only FY2026 2025-10-01 → 2026-09-30
Exclusions 18 never code together
D69code
Excludes1
  • benign hypergammaglobulinemic purpura (D89.0)D89.0
  • cryoglobulinemic purpura (D89.1)D89.1
  • essential (hemorrhagic) thrombocythemia (D47.3)D47.3
  • hemorrhagic thrombocythemia (D47.3)D47.3
  • purpura fulminans (D65)D65
  • thrombotic thrombocytopenic purpura (M31.19)M31.19
  • Waldenström hypergammaglobulinemic purpura (D89.0)D89.0
D69.4code
Excludes1
D50-D89chapter
Excludes2
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • certain conditions originating in the perinatal period (P00-P96)P00-P96
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • human immunodeficiency virus [HIV] disease (B20)B20
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes

No further instructional notes apply.

Index entries leading here filed at null

No alphabetic index entry points at this code.

Alongside this code 8 same parent — D69
Subordinate codes 3
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
no
Code set
FY2026
Parent
D69
Block
D65-D69
Siblings
8
Subordinate
3

Present FY2024–FY2027.